We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
As part of the Bristol Myers Squibb (BMS) commitment to patient care, we continue to explore bladder cancer, renal cell carcinoma, and prostate cancer through extensive clinical research.
divider
Step 1: Review the Protocols and Determine EligibilityReview trial details, including key inclusion/exclusion criteria, by clicking on the links in the "Jump to Studies" section above to determine the best trial for your patient. Step 2: Talk to Your PatientIf you find a trial that your patient might qualify for, talk to them about clinical trial participation. Step 3: Find Recruiting SiteSelect a convenient site location from a list of participating clinical trial sites. Step 4: Make ContactCall the principal investigator to discuss eligibility and enrollment for your patient. |
![]() |
divider
Below you will find a list of clinical studies that are sponsored by Bristol Myers Squibb (BMS). Click the links to get more information about each study.
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
A BMS-developed document written for patients to help explain how immuno-oncology works and how it is different from other therapies.
divider
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information